| 查看: 615 | 回复: 5 | |||
| 当前主题已经存档。 | |||
[交流]
FDA马上就要批准的新药
|
|||
|
Nuvigil Cephalon Receives Approvable Letter for Nuvigil (armodafinil) FRAZER, Pa., May 1, 2006 -- Cephalon, Inc. announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Nuvigil (armodafinil) Tablets. The company submitted a new drug application (NDA) on March 31, 2005, seeking to market Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS) and shift work sleep disorder (SWSD). FDA approval of Nuvigil is contingent upon finalizing the product label. "We are working closely with the FDA to move this application to an approval and expand our offering of wake-promotion choices for patients," said Dr. Paul Blake, Executive Vice President, Worldwide Medical and Regulatory Operations. "Based on the clinical trials, Nuvigil demonstrated a long duration of effect throughout the waking hours and we are excited at the potential to offer broader options to meet the needs of patients and physicians seeking treatment for excessive sleepiness." Armodafinil is a single-isomer formulation of modafinil, the active pharmaceutical ingredient contained in Provigil (modafinil) Tablets [C-IV]. Cephalon submitted data from four double-blind, randomized, placebo-controlled studies of Nuvigil in patients with excessive sleepiness associated with either narcolepsy, OSA/HS or SWSD to FDA for evaluation as part of the NDA. In these studies, Nuvigil was generally well tolerated, with a safety profile consistent with that observed in studies of Provigil. The most common adverse effects observed included headache, nausea, dizziness, insomnia and anxiety. As previously announced, the company submitted additional information to the FDA related to a possible case of Stevens Johnson Syndrome associated with its Sparlon (modafinil) application. In its Nuvigil approvable letter, the FDA indicated that the outcome of its review of this new information will be addressed directly in the label for Nuvigil. About Excessive Sleepiness (Hypersomnolence) Excessive sleepiness, medically known as hypersomnolence, is the primary symptom -- and often the most debilitating feature -- experienced by the millions of Americans who suffer from narcolepsy, OSA/HS, and SWSD. Despite this fact, it is estimated that 50 to 90 percent of the time, health care professionals fail to recognize that these patients are suffering from excessive sleepiness. The defining characteristic of excessive sleepiness is a consistent inability to stay awake and alert enough to safely and successfully accomplish tasks of daily living. Persons experiencing excessive sleepiness who seek medical attention typically complain of fatigue, tiredness, lapses of attention, lack of energy, low motivation, difficulty concentrating, disrupted sleep, snoring or difficulties at work. |
回复此楼» 猜你喜欢
脓毒症（盲肠结扎）
已经有22人回复
-
一志愿广医 药学专硕 总分383 已过四级 求调剂
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有81人回复
-
请问怎么才能在有羧基存在的情况下，只给酚羟基上甲基
已经有6人回复
-
参比制剂，自己做的PK数据与IF资料报道的数据相差很大
已经有2人回复
-
祈求中本子
已经有0人回复
-
各位大佬，H口面上什么时候会评？？？
已经有30人回复
-
2026年山东大学海洋学院生物与医药博士招生-李霞课题组
已经有0人回复
-
博士研究生招生
已经有0人回复
-
药理学、临床药学方向 调剂
已经有1人回复
0.5
2楼2006-05-14 11:44:59
3楼2006-05-14 14:04:36
4楼2006-05-16 10:25:58
0.5
| 谢谢分享，赞 |
5楼2006-05-16 10:30:55
6楼2006-05-18 16:52:43
投票:
